1
|
Kumaresan PR, Manuri PR, Albert ND, Singh H, Rabinovich B, Krishnamurthy J, Maiti SN, Simon O, Mi T, Lee D, Kontoyiannis D, Huls H, Cooper LJ. Dual-Specificity CAR+ T Cells to Target B-Cell Malignancies and Opportunistic Fungal Infection. Biol Blood Marrow Transplant 2014. [DOI: 10.1016/j.bbmt.2013.12.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
2
|
Kumaresan P, Manuri PR, Albert N, Rabinovich B, Olivares S, Maiti SN, Huls H, Lee DA, Kontoyiannis D, Cooper LJ. Bioengineering cytotoxic T cells to target opportunistic fungal infection. J Immunother Cancer 2013. [PMCID: PMC3991377 DOI: 10.1186/2051-1426-1-s1-p4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
3
|
Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008; 68:2961-71. [PMID: 18413766 PMCID: PMC2424272 DOI: 10.1158/0008-5472.can-07-5600] [Citation(s) in RCA: 197] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Genetic modification of clinical-grade T cells is undertaken to augment function, including redirecting specificity for desired antigen. We and others have introduced a chimeric antigen receptor (CAR) to enable T cells to recognize lineage-specific tumor antigen, such as CD19, and early-phase human trials are currently assessing safety and feasibility. However, a significant barrier to next-generation clinical studies is developing a suitable CAR expression vector capable of genetically modifying a broad population of T cells. Transduction of T cells is relatively efficient but it requires specialized manufacture of expensive clinical grade recombinant virus. Electrotransfer of naked DNA plasmid offers a cost-effective alternative approach, but the inefficiency of transgene integration mandates ex vivo selection under cytocidal concentrations of drug to enforce expression of selection genes to achieve clinically meaningful numbers of CAR(+) T cells. We report a new approach to efficiently generating T cells with redirected specificity, introducing DNA plasmids from the Sleeping Beauty transposon/transposase system to directly express a CD19-specific CAR in memory and effector T cells without drug selection. When coupled with numerical expansion on CD19(+) artificial antigen-presenting cells, this gene transfer method results in rapid outgrowth of CD4(+) and CD8(+) T cells expressing CAR to redirect specificity for CD19(+) tumor cells.
Collapse
Affiliation(s)
- Harjeet Singh
- Division of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Pallavi R. Manuri
- Division of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Simon Olivares
- Division of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Navid Dara
- Division of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Margaret J. Dawson
- Division of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Helen Huls
- Division of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Perry B. Hackett
- Department of Genetics, Cell Biology and Development, University of Minnesota, St. Paul, Minnesota
| | - Donald B. Kohn
- Division of Research Immunology/Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, California
| | - Elizabeth J. Shpall
- Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Richard E. Champlin
- Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Laurence J.N. Cooper
- Division of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
| |
Collapse
|
4
|
Nehete PN, Nehete BP, Hill L, Manuri PR, Baladandayuthapani V, Feng L, Simmons J, Sastry KJ. Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail. Virology 2007; 370:130-41. [PMID: 17920095 DOI: 10.1016/j.virol.2007.08.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2007] [Revised: 07/25/2007] [Accepted: 08/21/2007] [Indexed: 10/22/2022]
Abstract
Infection of Indian-origin rhesus macaques by the simian human immunodeficiency virus (SHIV) is considered to be a suitable preclinical model for directly testing efficacy of vaccine candidates based on the HIV-1 envelope. We used this model for prophylactic vaccination with a peptide-cocktail comprised of highly conserved HIV-1 envelope sequences immunogenic/antigenic in macaques and humans. Separate groups of macaques were immunized with the peptide-cocktail by intravenous and subcutaneous routes using autologous dendritic cells (DC) and Freund's adjuvant, respectively. The vaccine elicited antigen specific IFN-gamma-producing cells and T-cell proliferation, but not HIV-neutralizing antibodies. The vaccinated animals also exhibited efficient cross-clade cytolytic activity against target cells expressing envelope proteins corresponding to HIV-1 strains representative of multiple clades that increased after intravenous challenge with pathogenic SHIV(KU2). Virus-neutralizing antibodies were either undetectable or present only transiently at low levels in the control as well as vaccinated monkeys after infection. Significant control of plasma viremia leading to undetectable levels was achieved in majority of vaccinated monkeys compared to mock-vaccinated controls. Monkeys vaccinated with the peptide-cocktail using autologous DC, compared to Freund's adjuvant, and the mock-vaccinated animals, showed significantly higher IFN-gamma production, higher levels of vaccine-specific IFN-gamma producing CD4(+) cells and significant control of plasma viremia. These results support DC-based vaccine delivery and the utility of the conserved HIV-1 envelope peptide-cocktail, capable of priming strong cell-mediated immunity, for potential inclusion in HIV vaccination strategies.
Collapse
Affiliation(s)
- Pramod N Nehete
- Department of Veterinary Sciences, The University of Texas M. D. Anderson Cancer Center, Bastrop, TX 78602, USA
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Manuri PR, Nehete B, Nehete PN, Reisenauer R, Wardell S, Courtney AN, Gambhira R, Lomada D, Chopra AK, Sastry KJ. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 2007; 25:3302-10. [PMID: 17291642 PMCID: PMC2043498 DOI: 10.1016/j.vaccine.2007.01.010] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2006] [Revised: 12/20/2006] [Accepted: 01/04/2007] [Indexed: 11/20/2022]
Abstract
The E6 and E7 oncoproteins of the high-risk HPV type16 represent ideal targets for HPV vaccine development, they being consistently expressed in cervical cancer lesions. Since HPV-16 is primarily transmitted through genital mucosal route, mucosal immune responses constitute an essential feature for vaccination strategies against HPV-associated lesions. We present here evidence showing that mucosal immunization of mice by the intranasal route with a mixture of peptides E7(44-62) and E6(43-57) from the E7 and E6 oncoproteins of HPV-16, respectively, using a mutant cholera toxin adjuvant (CT-2*), primed strong antigen-specific cellular immune responses in systemic and mucosal tissues. Significant levels of IFN-gamma production by both CD4 and CD8 cells were observed along with CTL responses that were effective against both peptide-pulsed targets as well as syngeneic tumor cells (TC-1) expressing the cognate E6 and E7 proteins. Furthermore, mice immunized with the peptide mixture and CT-2* effectively resisted TC-1 tumor challenge. These results together with our earlier observations that T cell responses to these peptides correlate with recurrence-free survival in women after ablative treatment for HPV-associated cervical intraepithelial neoplasia, support the potential of these E6 and E7 peptides for inclusion in vaccine formulations.
Collapse
Affiliation(s)
- Pallavi R. Manuri
- Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, Bastrop, TX 77030
| | - Bharti Nehete
- Department of Veterinary Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, Bastrop, TX 77030
| | - Pramod N. Nehete
- Department of Veterinary Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, Bastrop, TX 77030
| | - Rose Reisenauer
- Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, Bastrop, TX 77030
| | - Seth Wardell
- Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, Bastrop, TX 77030
| | - Amy N. Courtney
- Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, Bastrop, TX 77030
| | - Ratish Gambhira
- Department of Veterinary Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, Bastrop, TX 77030
| | - Dakshyani Lomada
- Department of Carcinogenesis, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, Bastrop, TX 77030
| | - Ashok K. Chopra
- Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX 77555
| | - K. Jagannadha Sastry
- Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, Bastrop, TX 77030
- Department of Veterinary Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, Bastrop, TX 77030
| |
Collapse
|